Correct, so they can be fired for poor performance, not so they can receive a package.
i wouldn't say it is the best time. highly competitive market, a bit of uncertainty ( or headwinds as we like to say) with our decrease in volume. We have an incredible product on the horizon but several other companies are on track to release dual and tri-agonists in the diabetes and obesity space as well.